Table 4.
Bacteria | Hexane | CHCl3-MeOH | Aqueous | Levofloxacin |
---|---|---|---|---|
S. aureus (ATCC, 29213) | ≥500 | ≥500 | ≥500 | 3.12 |
S. epidermidis (ATCC, 14990) | ≥500 | ≥500 | ≥500 | 3.12 |
E. faecium (ATCC, 2127) | ≥500 | ≥500 | ≥500 | 3.12 |
E. coli (ATCC, 25922) | ≥500 | ≥500 | ≥500 | 3.12 |
P. aeruginosa (ATCC, 27853) | ≥500 | ≥500 | ≥500 | 3.12 |
K. pneumoniae (ATCC, 19606) | ≥500 | ≥500 | ≥500 | 3.12 |
A. baumanni (ATCC, 13883) | ≥500 | ≥500 | ≥500 | 3.12 |
Methicillin-resistant S.aureus (14-2095) | ≥500 | ≥500 | ≥500 | 12.5 |
Linezolid-resistant S. epidermidis (14-583) | ≥500 | ≥500 | ≥500 | 6.25 |
Vancomycin-resistant E. faecium (10-984) | ≥500 | ≥500 | ≥500 | 12.5 |
ESBL- resistant E.coli (14-2081) | ≥500 | ≥500 | ≥500 | 25.0 |
Carbapenem-resistant P. aeruginosa (13-1391) | ≥500 | ≥500 | ≥500 | 12.5 |
Oxacillin-resistant K. pneumoniae (17-1692) | ≥500 | ≥500 | ≥500 | 6.25 |
NDM-1+- resistant K. pneumoniae (14-3335) | ≥500 | ≥500 | ≥500 | 50.0 |
Carbapenem-resistant A. baumannii (12-666) | ≥500 | ≥500 | ≥500 | 12.5 |
ESBL: Extended spectrum β-lactamase; NDM-1+: New Delhi metallo-β-lactamase.